We’ve all had those moments when — even armed with an insurance card and/or a prescription savings card — we’ve had to walk away from a pharmacy without our prescriptions or decline an infusion at our doctor’s office or clinic because the price for treatment was simply too high. Today, we have the opportunity to make sure the new CGRP treatments for migraine aren’t priced out of reach.
Right now, the Institute for Clinical and Economic Review is reviewing erenumab, the first CGRP submitted for FDA approval, to determine if it is cost-effective. Its review and final report will have an enormous impact on the day to day lives of many of us living with migraine.
“Insurance companies will use ICER’s final report (as well as other information) when determining if they will cover this medicine (and other medicines in this class that are expected to follow), what tier the medicine will be in on the plan’s formulary, and what types of prior authorization or step therapy will be required. All of this will heavily impact the access migraine patients have to this new class of medicines.” – The Headache and Migraine Policy Forum, Patient Guide for ICER Review of New Migraine Medicine
The ICER is asking for patient input to accompany the droves of information it will be receiving from biotech companies, health economists, health plans, and medical providers. If you live with migraine, this is your chance to step in and explain what it is like to live with this disease every day and to shed a light on the disability experienced from migraine’s wide-range of symptoms. That information is vital to ensuring we all have affordable access to something that may significantly improve our quality of life.
Patient reports must be received by the ICER by November 30, 2017. This is a short deadline, but your input is crucial! Please consider submitting a response today. The link to the submission form is here: https://icer-review.org/patient-guide-to-open-input/.
If you aren’t sure what to say or how to say it, The Headache and Migraine Policy Forum has some tips and suggestions. They’re also hosting a free teleconference for patients on Tuesday, November 28 at 3:00pm ET, which will address the input period and how to make your voice heard. (Register here.)
It sometimes feel scary or overwhelming to define our experiences with chronic migraine, but now is the time to be heard. Please act now! United as one voice, we can make a difference.
Want to learn more about the CGRP drugs? Check out these posts on Migraine.com: